Gagandeep Kang   | Photo Credit: The Hindu

Several experts have raised concern over the “hasty approval” granted to the COVID-19 vaccines despite the lack of adequate efficacy data.

The Central Drugs Standard Control Organisation on Sunday accorded approval for restricted emergency use of the Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute of India (SII), and the indigenously developed vaccine Covaxin of Bharat Biotech.

Coronavirus | COVID-19 vaccine rollout possible in 10 days, says NITI Aayog member V.K. Paul

“I’m completely unaware of any data that suggests that Covaxin has any efficacy against any SARS-CoV-2 strain, let alone the U.K. strain,” Gagandeep Kang, Professor, Christian Medical College, Vellore, said in an interview to CNBC-TV18.

A doctor-cum-research head of a lab affiliated to a government research lab also expressed reservations. “At this point, I wouldn’t advise Covaxin. All we seem to know is that it’s safe and so may not be harmful but efficacy is a different matter and needs to be proved,” the expert said requesting anonymity.

“In the interest of transparency, we ask that the regulator share detailed rationale or the decision along with disclosure of data... We are baffled to understand what scientific logic has motivated top experts in the SEC (Subject Expert Committee) to approve this vaccine (Covaxin) post haste,” Malini Aisola, of the All India Drug Action Network, said in a statement.

Also read | BJP slams ‘vaccine sceptics’ in the Opposition

However, Randeep Guleria, Director, All India Institute of Medical Sciences, referred to Covaxin as a “backup vaccine” and added that it is to be used if it was not clear how efficacious the SII vaccine would be.

You have reached your limit for free articles this month.

Already have an account ? Sign in

Start your 14 days free trial. Sign Up

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper, crossword and print.

Dear reader,

We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.

Dear subscriber,

Thank you!

Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.

The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.

We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.

Suresh Nambath

Please enter a valid email address.

Most Shigella illnesses in healthy individuals are mild and symptoms subside in a few days

Subscribe to The Hindu now and get unlimited access.

Already have an account? Sign In

Start your 14 days free trial Sign Up

You can support quality journalism by turning off ad blocker or purchase a subscription for unlimited access to The Hindu.

Sign up for a 30 day free trial.